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Introduction
The RhoA GTPase (RhoA) is an essential, widely expressed, 
membrane-associated, guanine nucleotide–binding protein that 
contributes to various physiologic processes, including cell pro-
liferation, cytoskeletal dynamics, cell migration, cell metabolism, 
cytokinesis, and vesicle trafficking. It is frequently activated in 
advanced cancer and has also been implicated in cardiovascu-
lar and other diseases (Zhou and Zheng, 2013; Loirand, 2015; 
Ricker et al., 2016; Shimokawa et al., 2016; Wu and Xu, 2016).
RhoA acts as a molecular switch that is active when 
bound to GTP and inactive when bound to GDP. Regulation of 
RhoA by ligands for G protein–coupled receptors, especially 
those for lysophosphatidic acid (LPA), has been recognized for 
many years (Xiang et al., 2013; Yu and Brown, 2015). RhoA 
can also be regulated by adhesion and mechanical factors 
(Marjoram et al., 2014). In addition, receptor tyrosine kinases 
(RTKs) may up-regulate RhoA under some conditions, second-
ary to RTK-dependent activation of Rho guanine nucleotide 
exchange factors (Rho-GEFs), which catalyze replacement of 
GDP-bound RhoA with GTP-bound RhoA (Schiller, 2006).
RhoA can also be negatively regulated by Rho guanine 
nucleotide dissociation inhibitors, which sequester RhoA from 
the membrane (Garcia-Mata et al., 2011), and Rho GTPase-ac-
tivating proteins (RhoGAPs), which inactivate RhoA by cat-
alyzing the hydrolysis of GTP-bound RhoA to GDP-bound 
RhoA. However, their role in ligand-dependent RhoA signaling 
is not well established. Here, we report that ligand-dependent 
stimulation of RTKs in epithelial cells and fibroblasts can 
stimulate the activation of RhoA, and we determined that the 
activation was attributable to a previously unknown mecha-
nism, down-regulated activity of a specific, widely expressed 
RhoGAP DLC1 by a process that involves its phosphorylation 
by the serine/threonine kinase AKT.
Results
EGF, insulin, and insulin-like growth factor-1 
(IGF-1) positively regulate RhoA-GTP in a 
DLC1-dependent manner
We observed that stimulation of the EGF RTK, with its cognate 
ligand EGF, could activate RhoA in two nontransformed epithe-
lial cell lines, a fibroblast line, and a subset of cancer cell lines. 
We report several receptor tyrosine kinase (RTK) ligands increase RhoA–guanosine triphosphate (GTP) in untransformed 
and transformed cell lines and determine this phenomenon depends on the RTKs activating the AKT serine/threonine 
kinase. The increased RhoA-GTP results from AKT phosphorylating three serines (S298, S329, and S567) in the DLC1 
tumor suppressor, a Rho GTPase-activating protein (RhoGAP) associated with focal adhesions. Phosphorylation of the 
serines, located N-terminal to the DLC1 RhoGAP domain, induces strong binding of that N-terminal region to the 
RhoGAP domain, converting DLC1 from an open, active dimer to a closed, inactive monomer. That binding, which in-
terferes with the interaction of RhoA-GTP with the RhoGAP domain, reduces the hydrolysis of RhoA-GTP, the binding of 
other DLC1 ligands, and the colocalization of DLC1 with focal adhesions and attenuates tumor suppressor activity. DLC1 
is a critical AKT target in DLC1-positive cancer because AKT inhibition has potent antitumor activity in the DLC1-positive 
transgenic cancer model and in a DLC1-positive cancer cell line but not in an isogenic DLC1-negative cell line.
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Analysis of the lines unexpectedly found an excellent correla-
tion between the ability of EGF to increase RhoA-GTP and the 
expression of endogenous DLC1, which is a tumor-suppressor 
gene that encodes a 1091 amino acid protein containing a 
highly conserved RhoGAP domain and is required for its tu-
mor-suppressor function (Durkin et al., 2005; Lukasik et al., 
2011). The nontransformed lines H2071 (skin epithelial cells), 
FHL124 (lens epithelial cells), and H1634 (fibroblasts) all ex-
press DLC1, and EGF increased RhoA-GTP in each of them 
(Fig. 1 A), as did all four DLC1-positive cancer lines tested: 
two breast cancer lines, BT549 and MCF10Ca1h, and two 
non–small cell lung cancer (NSC LC) lines, H1703 and H157 
(Fig. 1 B and Fig. S1 A). However, EGF did not increase RhoA-
GTP in the DLC1-negative lines examined: two breast cancer 
lines, T47D and MDA-MB-468, and two NSC LC lines, H358 
and A549 (Fig. 1 C and Fig S1 B).
To determine whether the EGF-induced increase in 
RhoA-GTP depended on DLC1, the effect of DLC1 knock-
down by siRNA was tested in DLC1-positive lines: two non-
transformed, H2071 and H1634, and two transformed lines, 
H1703 and BT549. The siRNAs efficiently suppressed DLC1 
expression in each line, leading, as expected, to an increase 
in basal RhoA-GTP levels (Fig.  1, D and E; and Fig. S1, C 
and D). Although EGF activated the EGF receptor (EGFR), 
as measured by EGFR-Y845 phosphorylation, whether or not 
the cells had been treated with DLC1 siRNAs, EGF increased 
RhoA-GTP only under conditions with continued expression 
of DLC1 (Fig. 1, D and E; Fig. S1, C and D; and Fig. S1 E, 
which shows the relative DLC1 expression of all lines used 
in this study). Thus, the EGF-induced increase in RhoA-GTP 
depended on the presence of DLC1.
In a preliminary exploration of the mechanism by which 
EGF might be regulating DLC1, the level of serine phosphor-
ylation of DLC1 increased after EGF treatment (Fig. S1 F), 
whereas tyrosine phosphorylation was unchanged (unpublished 
data). One serine/threonine kinase known to be activated by 
EGF is AKT (Fig. S1 G; Garay et al., 2015; Nishimura et al., 
2015). A previous study identified one serine in DLC1 (S567) 
as being phosphorylated by AKT (Ko et al., 2010), which de-
creased the growth inhibitory activity of DLC1 by a mecha-
nism the authors concluded was not associated with a change in 
RhoA-GTP. Two additional serines in DLC1 are possible AKT 
substrates (S298 and S329), but Ko et al. (2010) concluded they 
were not phosphorylated.
We evaluated whether AKT activation might be associated 
with the EGF-induced stimulation of RhoA. As expected, EGF 
treatment led to increased AKT activity, as measured by AKT-
S473 phosphorylation, which was not attenuated by siRNA 
Figure 1. EGF-induced AKT activity increases RhoA-GTP through DLC1. (A and B) EGF increases RhoA-GTP, but not total Rho, in DLC1-positive nontrans-
formed (A) and cancer (B) cells. (C) EGF does not alter RhoA-GTP in DLC1-negative lines. (D and E) DLC1 siRNA renders RhoA-GTP unresponsive to EGF. 
EGF-induced EGFR activity (phosphorylation of EGFR-Y845) and AKT activity (phosphorylation of AKT-S473) in DLC1-expressing and DLC1-knockdown 
cells. DLC1 knockdown abrogates the ability of EGF to increase RhoA-GTP in nontransformed (D) and cancer (E) cells. (F) MK-2206 decreases RhoA-GTP 
in DLC1-positive lines (BT549 and H1703) but not in DLC1-negative lines (T47D and H358), although MK-2206 inhibits AKT activity in all lines. (G) MK-
2206 suppresses RhoA-GTP in DLC1-expressing cells but not in DLC1-knockdown cells. (H) Stable DLC1 transfection of DLC1-negative H358 cells decreases 
basal RhoA-GTP and enables MK-2206 to further reduce RhoA-GTP. MK-2206 does not affect RhoA-GTP in parental H358 cells. Each graph shows relative 
RhoA-GTP means ± SD from three experiments. Parametric two-tailed t tests were performed for statistical analysis.
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knockdown of DLC1 (Fig. 1, D and E; and Fig. S1, C and D). 
To explore the temporal relationship between EGF-induced 
changes in EGFR activation, AKT activation, and RhoA-
GTP level, we evaluated two nontransformed DLC1-positive 
lines (H2071 and H1634) with low AKT activity and three 
DLC1-positive cancer lines (BT549, H1703, and H157) with 
high AKT activity. After 15 min of EGF treatment, EGFR was 
activated in each line; it remained high at 30 min and then de-
creased at 60 and 120 min (Fig. S1 H). The kinetic profiles of 
AKT activity, as measured by pAKT-S473 and RhoA-GTP, par-
alleled that of EGFR activity (Fig. S1 H).
To test whether AKT activity was mechanistically linked 
to the observed changes in RhoA-GTP, two DLC1-positive 
lines (BT549 and H1703) and two DLC1-negative lines (T47D 
and H358) were treated with an AKT inhibitor, MK-2206 (Hirai 
et al., 2010). Although AKT activity was efficiently inhibited 
in all lines, MK-2206 substantially reduced RhoA-GTP in the 
DLC1-positive lines (Fig. 1 F, two left columns), but not in the 
DLC1-negative lines (Fig. 1 F, two right columns). To verify that 
the observed effect of AKT activity on RhoA-GTP depended on 
DLC1, H1703 cells in which DLC1 had been knocked down by 
siRNAs were treated with MK-2206. Under those conditions 
of low DLC1, MK-2206 did not affect RhoA-GTP (Fig. 1 G). 
We also examined MK-2206 on an H358-derived cell line that, 
although the parental line does not express DLC1, had been sta-
bly transfected with DLC1. MK-2206 had no effect on RhoA-
GTP in the parental cells, but it did reduce RhoA-GTP in the 
DLC1 transfectant (Fig. 1 H). Thus, AKT-regulated RhoA-GTP 
was dependent on DLC1. AKT also negatively regulated the 
RhoGAP activity of other DLC family members, DLC2 and 
DLC3 (Lukasik et al., 2011; Braun and Olayioye, 2015), but 
the effect of AKT inhibition on DLC2 and DLC3 on RhoA-
GTP was less than that on DLC1 when cells transfected with the 
DLC genes were treated with MK-2206 (Fig. S1 I).
Because EGFR is an RTK, we explored whether ligands 
that activate other RTKs and AKT might also increase RhoA-
GTP. Analogous to EGF, insulin (Fig. S2 A) and IGF-1 (Fig. S2 
B) activated AKT in all lines tested, but they increased RhoA-
GTP only in the DLC1-positive lines.
We also examined LPA, a ligand frequently used to in-
crease RhoA-GTP, to see whether DLC1 was involved in that 
process. However, LPA, which increases RhoA-GTP through 
G protein–coupled receptors, rather than through RTKs (Yu 
and Brown, 2015), did not activate AKT and induced RhoA-
GTP in a DLC1-independent manner in all lines examined 
(Fig. S2, C–E). Thus, LPA and RTK ligands induce RhoA-GTP 
by distinct mechanisms.
LPA treatment also enabled us to verify that the observed 
inability of AKT to increase RhoA-GTP in cells that were defi-
cient for DLC1 expression (Figs 1, D and E; and Fig. S1, C and 
D) was not because they were incapable of further increasing 
their RhoA-GTP. Indeed, LPA increased RhoA-GTP in cells 
that were DLC1-negative (Fig. S2 C, right) and in cells whose 
DLC1 had been subjected to knockdown by siRNAs (Fig. S2 E).
AKT forms an endogenous complex 
with DLC1 and interacts with two 
regions of DLC1
The aforementioned results suggest that AKT might bind 
DLC1. To determine whether the two proteins form a complex 
in cells, we performed coimmunoprecipitation (coIP) exper-
iments in cells expressing both proteins: two nontransformed 
lines (H2071 and H1634) and three cancer lines (BT549, 
H1703, and H157). DLC1 and AKT formed a complex in each 
line, whether cell lysates were immunoprecipitated (IP), first 
with a DLC1 antibody, and then immunoblotted (IB) for AKT 
(Fig. 2, A and B; and Fig. S3, A, C, and D) or by the reciprocal 
coIP (Fig. 2, C and D; and Fig S3 B), implying the interaction 
is physiologically relevant.
Some AKT associated with DLC1 was inferred to be en-
zymatically active because positive coIP results were obtained 
from all three lines when the lysates were IP with a phospho- 
specific antibody against pAKT-S473, followed by IB for DLC1 
(Fig. 2, E and F; and Fig. S3 E). However, MK-2206 did not 
reduce the amount of the AKT/DLC1 complex (Fig. S3, F–J), 
and AKT activity stimulation by EGF did not increase the AKT/
DLC1 complex (Fig. S3, K–N), implying complex formation 
does not depend on the enzymatic activity of AKT. AKT also 
formed a complex with DLC2 and DLC3, but less efficiently 
than it did with DLC1 (Fig. 2, G and H). Colocalization of AKT 
and DLC1 was confirmed by confocal microscopy in the two 
NSC LC lines, with colocalization coefficients of ∼0.60 (Fig. 2, 
I and J), and by proximity ligation assay (PLA; Fig. 2, K and L).
DLC1 has four recognized regions: an N-terminal SAM 
domain, a linker region, a RhoGAP domain, and a C-terminal 
STA RT domain (Fig.  3  A; Tripathi et al., 2014). To map the 
regions of DLC1 required for AKT binding, lysates from 
human embryonic kidney (HEK) 293T cells expressing various 
GFP-tagged DLC1 fragments, which were numbered by their 
respective N-terminal– and C-terminal–encoded amino acids 
(Fig. 3 A), were IP with AKT antibody, followed by IB with 
a GFP antibody. Interestingly, AKT bound to some nonover-
lapping N-terminal and C-terminal DLC1 fragments, implying 
that AKT interacts with more than one region of DLC1 (Fig. 3, 
B and C). To more precisely map the DLC1 regions required 
for AKT binding, smaller N-terminal and C-terminal DLC1 
fragments were used. N-terminal AKT binding required at least 
some DLC1 amino acids 300–400 because DLC1 (80–400) 
was positive, whereas DLC1 (80–300) was negative (Fig. 3, D 
and E). The C-terminal DLC1 fragment that bound AKT was 
mapped to the RhoGAP domain because AKT interacted with 
DLC1 (609–850) but not with DLC1 (850–1091; Fig. 3 F).
AKT phosphorylates three serines in DLC1
Although a previous study (Ko et al., 2010) concluded only 
S567 in DLC1 was phosphorylated by AKT, we evaluated 
whether S298 and/or S329 (Fig. 3, A and I) might be phosphor-
ylated under our growth conditions using 32P labeling. First, we 
confirmed that most of the serine phosphorylation of DLC1 was 
dependent on AKT by treating the cells with MK-2206, which 
greatly reduced both AKT activity and serine phosphorylation 
of DLC1 (Fig. 3 G). Using partially purified, full-length DLC1, 
we observed DLC1 was strongly phosphorylated by AKT ki-
nase in vitro, unlike the GFP control (Fig. 3 H, left, lanes 1 and 
2). Thus, DLC1 is a direct substrate for AKT. DLC2 and DLC3 
were also phosphorylated in vitro but less strongly than DLC1 
(Fig. 3 H, left; and Fig. S4 A; see Fig. 3 I for consensus motifs).
To determine whether S298, S329, and S567 are the major 
AKT phosphorylation sites in DLC1, all three were mutated to 
alanine (DLC1-3A), resulting in a drastically reduced in vitro 
phospho signal (Fig.  3  H, middle, lane 4). When serine-to- 
alanine double mutants were analyzed, the phospho signal 
was reduced but was greater than the DLC1-3A mutant; sin-
gle serine-to-alanine mutants retained a strong phospho signal 
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(Fig.  3  H, middle and right; S329A mutant not depicted). 
Liquid chromatography–mass spectrometry confirmed those 
results, suggesting that all three serines were phosphorylated 
under these growth conditions because the analysis of the par-
tially purified DLC1 from cells transfected with DLC1-WT or 
the DLC1-3A mutant detected phosphorylation in S298, S329, 
and S567 in the relevant DLC1-WT peptides, but not in the 
DLC1-3A mutant (Fig. 3 J and Fig. S4 B).
Phosphorylation of the three “AKT” 
serines in DLC1 greatly attenuates its 
RhoGAP and tumor-suppressor functions
Our observation that AKT could increase RhoA-GTP in a 
DLC1-dependent manner suggested that AKT phosphorylation 
of the three DLC1 serines would attenuate its RhoGAP and 
tumor suppressor functions. To evaluate those possibilities, we 
compared the activities of DLC1-WT with the nonphosphory-
latable, triple alanine mutant (DLC1-3A). We also constructed 
and analyzed the phosphomimetic, triple serine-to-aspartate 
mutant (DLC1-3D) and included a “GAP-dead” mutant 
(DLC1-R718A) as a control.
In H1703 cells that stably expressed similar levels of the 
constructs, the RhoA-GTP level in the DLC1-3D transfectant 
was similar to the GAP-dead DLC1 (DLC1-R718A; Fig.  4, 
A and B). However, the RhoA-GTP in the DLC1-3A mutant 
was at least as low as that induced by DLC1-WT. Analogous 
results were seen when the DLC1 mutants were analyzed for 
Rho kinase (ROCK) activity (Fig. 4 C), in vitro RhoGAP activ-
ity (Fig. 4 D), and phosphorylation of myosin regulatory light 
chain (pMRLC; Fig. 5 A), a major downstream effector of the 
RhoA-ROCK pathway. By immunofluorescence, cells trans-
fected with GFP, DLC1-3D, or DLC1-R718A showed similar 
strong staining of pMRLC (Fig. 4 E), with well-formed stress 
fibers (Fig. 4 F). In contrast, cells transfected with DLC1-WT 
or DLC1-3A showed less pMRLC staining, fewer stress fibers, 
and few, if any, concave boundaries, consistent with reduced 
RhoA-ROCK signaling and reduced cell contraction.
When less-drastic individual or combined mutants were 
analyzed in DLC1-negative A549 cells, RhoA-GTP was in-
versely related to the number of phosphomimetic serine- 
to-aspartate (S-to-D) mutations in DLC1 (Fig.  5, B and C). 
Figure 2. Endogenous protein complex formation between DLC1 and AKT. (A–D) Complex between DLC1 and AKT. (A and B) Lysates from BT549 and 
H1703 were IP with DLC1 or mock IgG antibodies, followed by IB with AKT (top) or DLC1 (bottom) antibodies. WCE, whole cell extract. (C and D) AKT/
DLC1 complex by reciprocal coIP. (E and F) Some AKTs associated with DLC1 were enzymatically active. Protein complex between DLC1 and kinase-active 
AKT (pAKT-S473). (E) Lysates from BT549 cells were IP with pAKT-S473 or mock IgG antibodies followed by IB with DLC1 (top) or pAKT-S473 (bottom) 
antibodies. (F) Enzymatically active complex was detected by the reciprocal coIP. (G and H) AKT interacts with DLC2 and DLC3 but less strongly than with 
DLC1. (G) Lysates from HEK 293T cells transfected with GFP-tagged DLC1, DLC2, or DLC3 were IP with AKT antibody, followed by IB with GFP (top) or 
AKT (bottom) antibodies. (H) Expression of GFP and various GFP-tagged DLC constructs for G. (I–L) Colocalization of AKT with DLC1. Colacali. coeff., 
colocalization coefficient. (I) H1703 cells were stained with DLC1 (red) and AKT (green) antibodies. Colocalization of DLC1 and AKT is highlighted in 
yellow (arrow) in the merged image. Overlapping colocalization coefficient means ± SD (below panel) was calculated from 16 cells randomly selected 
from several fields. Bar, 20 µm. (J) Colocalization of endogenous DLC1 with AKT in H157 cells. Experimental conditions were similar to those in I.   
Bar, 20 µm. (K and L) Colocalization of DLC1 and AKT was confirmed by PLA. Bars, 10 µm.
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These results suggest the effects of each serine phosphorylation 
on RhoA-GTP are additive.
We examined MK-2206 treatment of stable DLC1 trans-
fectants in DLC1-negative H358 cells. The findings verified that 
MK-2206 did not affect RhoA-GTP in DLC1-3A or DLC1-3D 
mutants, although, consistent with earlier results (Fig. 1 H), it 
did decrease RhoA-GTP for DLC1-WT (Fig. 5, D and E).
We had previously found that CDK5 phosphorylation 
of four other serines in the linker region (S120, S205, S422, 
and S509) increased the RhoGAP activity of DLC1 (Tripa-
thi et al., 2014), which is the opposite of the effects of AKT 
phosphorylation of DLC1. To determine whether AKT phos-
phorylation of DLC1 was phenotypically dominant over CDK5 
phosphorylation of DLC1, we studied A549 cells, in which both 
endogenous CDK5 and endogenous AKT are active and stably 
transfected with mutants of all four “CDK5” serines in DLC1 
(DLC1-4A-CDK5 and DLC1-4D-CDK5) and those transfected 
with the AKT serine mutants DLC1-3A and DLC1-3D mutants 
described here (for clarity, they are designated DLC1-3A-AKT 
and DLC1-3D-AKT in this paragraph), as well as with WT 
DLC1. The effects of AKT inhibition or CDK5 inhibition on 
the phosphorylation of the AKT-serines and the CDK5-ser-
ines and on RhoA-GTP were evaluated. Consistent with AKT 
activity being phenotypically dominant over CKD5 activity, 
CKD5 inhibition with roscovitine did not increase RhoA-GTP 
for the DLC1-3A-AKT mutant, but AKT inhibition with MK-
Figure 3. AKT binds two nonoverlapping regions of DLC1 and phosphorylates three serines in DLC1. (A) Schematic representation of DLC1 domains. 
DLC1-3A and DLC1-3D mutants have three AKT phosphorylatable serines mutated to alanine or aspartate, respectively. All constructs were GFP tagged. 
(B and C) AKT binds to N- and C-terminal sequences of DLC1. WCE, whole cell extract. (B) Lysates from HEK 293T cells transfected with indicated DLC1 
constructs were IP with AKT antibody, followed by IB with GFP (top) and AKT (bottom) antibodies. (C) Expression of DLC1 constructs for B. (D and F) Ex-
perimental conditions were as in B and C. (D) AKT binds to DLC1 amino acids 80–400 but not to the other N-terminal DLC1 fragments. (E) Expression of 
DLC1 constructs for D. (F) AKT binds to the RhoGAP domain (amino acids 609–850) of DLC1, but not the C-terminal fragment (amino acids 850–1091; 
top). IP pellets were IB with AKT antibody (middle). Expression of GFP and DLC1 constructs (bottom). (G) MK-2206 reduces phosphorylation of AKT ser-
ines in DLC1 (pSer) without reducing total DLC1. Lysates from BT549 and H1703 cells, treated without or with MK-2206, which reduced pAKT-473 but 
not its protein level, were IP with DLC1 antibody followed by IB with phospho-AKT substrate-specific (top) or DLC1 antibodies. MK-2206 inhibited AKT 
activity in both lines (bottom). (H) AKT phosphorylates DLC1 in vitro. (H, top) IP DLC1-WT from transfected HEK 293T cells was strongly phosphorylated by 
recombinant AKT kinase (left, middle lane), as detected with 32P autoradiography; GFP control was negative (lane 1 in both left and middle). Combined 
DLC1-S329A,S567A mutant was weakly phosphorylated (middle, lane 3), but the DLC1-3A mutant (combined serine-to-alanine mutation of S298, S329, 
and S567) gave no phospho-signal (middle, lane 4). DLC2 was also phosphorylated (left, lane 3) but weaker than it was with DLC1. (H, bottom) Expres-
sion of DLC1 constructs. (I) Consensus motifs for AKT kinase for indicated serines (red) in DLC1, DLC2, and DLC3. (J) Phosphorylation of DLC1 by AKT in 
cells. DLC1 phosphopeptides were detected by mass spectrometry. The AKT phosphorylation signals were fully localized to the indicated serines and were 
absent from the DLC1-3A mutant protein. o  
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2206 did reduce RhoA-GTP for the DLC1-4A-CDK5 mu-
tant (Fig. S5, A and B).
To assess the biological significance of DLC1 phosphory-
lation by AKT, we evaluated the DLC1-3A and DLC1-3D mu-
tants in several bioassays. Stable DLC1-WT transfectants in the 
H358 line reduced the following functional bioassays: anchor-
age-independent cell growth (Fig. 6, A and B), RhoA-GTP level 
(Fig. 6, C and D), transwell cell migration (Fig. 6, E and F), and 
xenograft tumors in immunodeficient mice (Fig. 6, G and H). 
The DLC1-3D mutant was as deficient as the GAP-dead DLC1-
R718A mutant in those bioassays, whereas the DLC1-3A mu-
tant was even more active than DLC1-WT.
AKT phosphorylation of DLC1 increases 
binding between the linker region and the 
RhoGAP domain
Given the location of the three AKT serine phosphorylation 
sites in the linker region (Fig. 3 A), we speculated their phos-
phorylation might attenuate the RhoGAP activity of DLC1 
by increasing the binding of the linker region to the RhoGAP 
domain, placing the protein in a closed conformation. Such a 
mechanism would be the opposite of the one by which CDK5 
activates DLC1 (Tripathi et al., 2014).
To test that hypothesis, we generated three isogenic 
versions of a GST-tagged DLC1 linker region encoding 
amino acids 80–600, which contains the three serines phos-
phorylatable by AKT: a WT fragment [GST-DLC1 (80–
600)–WT], its nonphosphorylatable 3A mutant [GST-DLC1 
(80–600)–3A], and its phosphomimetic 3D mutant [GST-
DLC1 (80–600)–3D]. A549 cells, which have high AKT 
activity and are DLC1 negative, were cotransfected with a 
fragment encoding the GFP-tagged RhoGAP domain [GFP-
DLC1 (609–878)] and each of the linker region constructs. 
Consistent with our hypothesis, GST pull-downs indicated 
the RhoGAP domain efficiently formed a complex with GST-
DLC1 (80–600)–WT and with the GST-DLC1 (80–600)–3D 
Figure 4. Phosphomimetic DLC1-3D mutant has attenuated RhoGAP activity. (A) Graph shows relative RhoA-GTP means ± SD for indicated DLC1 mutants 
from three experiments. DLC1-3D mutant is as defective as GAP-dead DLC1-R718A mutant for reducing RhoA-GTP. DLC1-3A mutant is more active than 
DLC1-WT. Parametric two-tailed t tests were performed for statistical analysis. P < 0.01 for DLC1-WT and P < 0.001 for DLC1-3A compared with other 
transfectants. (B) Expression of stable DLC1 transfectants in H1703 cells for A. Lysates were IB with GFP (top) or DLC1 (bottom) antibodies. (C) Experimental 
conditions and data displays were similar to A, but for ROCK activity, analogous to the results in A. (D) Relative RhoGAP activity of DLC1 mutants. In vitro 
RhoA-GTP hydrolysis by DLC1 mutants. Hydrolysis of DLC1-3D was similar to GFP control or GAP-dead DLC1-R718A. Hydrolysis of DLC1-3A was greater 
than it was with DLC1-WT. (E) Cells with stably transfected DLC1-WT or DLC1-3A have less phospho-MRLC (red) compared with the other transfectants. 
DAPI (blue) represents the nuclei. Bar, 100 µm. (F) Cells transfected with DLC1-WT or DLC1-3A have fewer concave boundaries, consistent with reduced 
contraction, and fewer stress fibers (green), especially in the central region, compared with the other transfectants. The confocal images are representative 
of most of the cells. Bar, 20 µm.
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mutant, whereas the GST-DLC1 (80–600)–3A mutant had 
weaker binding (Fig. 7 A). Binding of the constructs in A549 
cells was also analyzed by immobilization-free, microscale 
thermophoresis (MST), which provides quantitative in vitro 
measurements of protein interactions in close-to-native con-
ditions. Similar to the GST pull-down assays, binding be-
tween the RhoGAP domain and DLC1 (80–600)–WT was 
similar to that of the phosphomimetic DLC1 (80–600)–3D 
mutant, whereas the nonphosphorylatable DLC1 (80–600)–
3A mutant did not bind the RhoGAP domain even at very 
high concentrations (Fig. 7 B).
AKT phosphorylation of DLC1 decreases 
the binding of RhoA-GTP and other ligands
The linker region of DLC1 also binds tensin (Liao et al., 2007; 
Qian et al., 2007) and talin (Li et al., 2011), two ligands im-
plicated in integrin signaling, whose binding contributes to 
the tumor-suppressor function of DLC1. We speculated the 
closed conformation induced by AKT phosphorylation might 
also reduce DLC1 binding of tensin and talin. Indeed, they 
interacted less efficiently with the phosphomimetic full-length 
DLC1-3D mutant than they did with DLC1-WT (Fig.  7, C 
and D) in HEK 293T cells, which have lower AKT activity 
than A549 cells. The decreased binding was attributable to 
the closed conformation, rather than to a putative, intrinsic 
decrease in binding to the linker region because the N-termi-
nal 3D fragment [GST-DLC1 (80–600)–3D] bound tensin and 
talin as efficiently as the N-terminal WT fragment [GST-DLC1 
(80–600)–WT] or the N-terminal 3A fragment [GST-DLC1 
(80–600)–3A; Fig. S5, C and D].
The results also suggested the closed conformation of 
DLC1 would reduce the efficiency of the interaction between 
the RhoGAP domain and RhoA-GTP. Consistent with that 
hypothesis, the DLC1-3D mutant, which places the protein in 
the closed conformation, bound RhoA-GTPγS in vitro almost 
as weakly as the GAP-dead DLC1-R677A mutant, which is 
known to have reduced RhoA-GTPγS binding (Fig.  7, E and 
F; Jaiswal et al., 2014). In contrast, the binding efficiency of 
RhoA-GTPγS to the DLC1-3A mutant, which is in the open 
conformation, was at least as strong as that of DLC1-WT.
Figure 5. RhoGAP activity of DLC1 is inversely related to the number of S-to-D mutations in DLC1. (A) DLC1-WT–positive control has less pMRLC (P < 
0.01) than GFP-transfected cells have. DLC1-3D mutant is as defective as a GAP-dead DLC1-R718A mutant for inhibition of pMRLC. Graph shows relative 
pMRLC/MRLC means ± SD from three experiments. Parametric two-tailed t tests were performed for statistical analysis. (B and C) RhoA-GTP (top) and total 
Rho (middle) in individual or combined mutants of DLC1 transfected in the DLC1-negative A549 cells. RhoA-GTP levels are inversely related to the number 
of S-to-D mutations, and the degree of RhoGAP reduction is additive for each mutation. Expression of indicated DLC1 constructs (bottom). Graph shows 
relative RhoA-GTP means ± SD from two experiments. (D) Effect of MK-2206 on RhoGAP activity of DLC1 mutants. In control panel, RhoA-GTP was reduced 
by DLC1-WT or DLC1-3A mutant compared with GFP control, DLC1-3D, or DLC1-R718A. MK-2206 further reduces RhoA-GTP in DLC1-WT (compare lanes 
2 and 7). MK-2206 does not influence RhoA-GTP in GFP, DLC1-3A, DLC1-3D, or DLC1-R718A. (E) Graph shows relative RhoA-GTP means ± SD from 
three experiments, as in D. A significant decrease (P < 0.01) in RhoA-GTP in DLC1-WT–transfected cells by MK-2206 (compare DLC1-WT control versus 
DLC1-WT treated with MK-2206).
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DLC1 is mainly a monomer in the closed 
conformation induced by AKT
Because active DLC1 is a dimer (Ko et al., 2013), we asked 
whether DLC1 might be a monomer when in the closed con-
formation induced by AKT. To evaluate that possibility, we 
cotransfected GST-tagged, full-length DLC1 together with 
GFP-tagged, full-length DLC1 into A549 cells, performed GST 
pull-downs, and IB the pulled-down proteins for GFP (Fig. 7, G 
and H). Consistent with the Ko et al. (2013) findings, there was 
a strong GFP band in cells cotransfected with the DLC1-3A 
mutant, which has the open conformation. However, the GFP 
band was much weaker with the DLC1-3D mutant, which is 
closed, implying most of that mutant protein is monomeric. 
The intensity of the GFP band with DLC1-WT, which is mainly 
closed, was reduced compared with DLC1-3A, consistent with 
the closed conformation being a monomer. When the cells were 
treated with MK-2206, the intensity of the GFP band from the 
DLC1-WT transfectants increased, consistent with them be-
coming active dimers. We conclude that the closed conforma-
tion induced by AKT arises via an intramolecular interaction 
because that form is mainly monomeric.
AKT phosphorylation of DLC1 alters its 
focal adhesion (FA) localization
Part of the linker region has been referred to as the FA tar-
geting domain (Liao et al., 2007) because it participates in 
DLC1 localization to FAs. We used H1703 cells to test the 
hypothesis that FA localization would be affected by the 
closed conformation induced by AKT (Fig. 8). Consistent 
with that prediction, the phosphomimetic DLC1-3D mutant 
colocalized poorly with the FA protein vinculin (Fig. 8 D; 
colocalization coefficient = 0.12), whereas the nonphos-
phorylatable DLC1-3A mutant was strongly colocalized 
(Fig. 8 C; colocalization coefficient = 0.78). Colocalization 
was intermediate for the DLC1-WT (Fig. 8 B; colocaliza-
tion coefficient = 0.55), suggesting that some DLC1-WT is 
phosphorylated by AKT in H1703, which implies that MK-
2206 treatment could further increase its FA colocaliza-
tion. Consistent with that hypothesis, MK-2206 treatment 
increased FA colocalization of the DLC1-WT (Fig.  8  F; 
colocalization coefficient = 0.79) but did not affect colo-
calization of GFP or the DLC1-3A or DLC1-3D mutants 
(Fig. 8, E, G, and H).
Figure 6. DLC1-3D mutant has attenuated tumor-suppressor functions. (A and B) Anchorage-independent growth: DLC1-3D is as defective as GAP-dead 
DLC1-R718A; DLC1-3A is even more active than DLC1-WT. (A) Photomicrographs of representative agar colonies. Bar, 2 mm. (B) Quantification of agar 
colonies (>0.4 mm) from three experiments. (C and D) RhoA-GTP of the transfected mutants parallels the results in A and B. (D) Immunoblots for RhoA-GTP 
and total Rho, as shown in C, were quantified, and the ratio of RhoA-GTP to total Rho was normalized. Parametric two-tailed t tests were performed for sta-
tistical analysis. A significant decrease in RhoA-GTP/total Rho in DLC1-WT (P < 0.01) and in DLC1-3A (P < 0.001) compared with GFP control, DLC1-3D, 
or DLC1-R718A transfected cells. Graph shows relative RhoA-GTP means ± SD from three experiments. (E and F) Cell migration assay: DLC1-3D is as 
defective as GAP-dead DLC1-R718A; DLC1-3A is similar to DLC1-WT. (E) Photomicrograph of representative migrated cells. Bar, 100 mm. (F) Graph shows 
transwell cell migration from three experiments. (G and H) Xenograft tumors from mice excised 6 wk after injecting stable transfectants. (G) Photographs 
of excised tumors. (H) Graph shows tumor weight (g) means ± SD for each group. Parametric two-tailed t tests were performed for statistical analysis. 
DLC1-3D is as defective for tumor suppression as GAP-dead DLC1-R718A. The tumor suppressor activity of DLC1-3A mutant is even greater than DLC1-WT. 
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AKT inhibition has antitumor activity in 
DLC1-positive tumors
One potential implication of these findings is that inhibition of 
AKT, a candidate approach for cancer treatment (Nitulescu et 
al., 2016), could reverse the attenuation of DLC1 activity that 
depends on AKT. Although AKT has many targets, if DLC1 
is a critical one, AKT inhibition might have more potent ac-
tivity against tumors that express WT DLC1 compared with 
those that do not. To test that possibility, we evaluated MK-
2206 in the MMTV-PyMT transgenic breast cancer model, in 
which the MMTV promoter drives the polyomavirus middle T 
antigen, which stimulates AKT (Meili et al., 1998; Summers et 
al., 1998). First, we confirmed that, compared with mammary 
epithelial tissue from pregnant mice, MMTV-PyMT tumors 
have greater AKT activity (Fig.  9  A and Fig. S5 E). Consis-
tent with the cell culture findings that linked AKT, DLC1, 
and RhoA-GTP, AKT activity in the tumors was associated 
with higher levels of RhoA-GTP, greater downstream effector 
phospho-MRLC, and greater phosphorylation of DLC1 serine 
residues (Fig. 9 A and Fig. S5, E and F). We then treated ran-
domized tumor-bearing mice with oral MK-2206 for 5 d, which 
induced a threefold reduction in mean tumor weight (Fig. 9 B) 
and was correlated with decreased AKT activity and reduced 
RhoA-GTP, phospho-MRLC, and DLC1 serine phosphoryla-
tion by AKT (Fig. 9 A and Fig. S6, A and B).
We speculated the DLC1 reactivation from MK-2206 
treatment had contributed to the observed antitumor activ-
ity. To evaluate that hypothesis more directly, we used two 
isogenic tumor cell lines, from H358, which differed only in 
their DLC1 expression (GFP versus GFP-DLC1-WT), and 
evaluated the ability of MK-2206 to affect their growth in 
agar and tumor growth in nonobese diabetic–severe combined 
Figure 7. AKT phosphorylation of the AKT serines in DLC1 reduces several DLC1 functions. (A and B) Phosphorylation increases binding of linker region 
to RhoGAP domain. (A) GST-tagged N-terminal DLC1 fragment or its indicated mutants were cotransfected with GFP-tagged RhoGAP domain of DLC1 in 
DLC1-negative A549 cells, which have high AKT activity. The expressed GST-tagged fragments were pulled down with GST antibody, followed by IB with 
GFP antibody (top). IB with GFP (middle) or GST (bottom) antibodies show expression of DLC1 fragments in whole cell extract (WCE). (B) In vitro binding 
by MST of DLC1 fragments. The partially purified WT and 3D mutant demonstrate binding to the RhoGAP domain by the s-shape of the binding plot; the 
3A mutant shows no binding (flat line). (C and D) Phosphorylation decreases tensin and talin binding to DLC1. In HEK 293T, which have low AKT activity, 
GST-tensin (1508–1786; C) or GST-talin (1288–1646; D) bind more efficiently to DLC1-WT or DLC1-3A compared with DLC1-3D mutant (top). IB with 
GST (middle) or GFP (bottom) antibodies show expression of each construct in WCE. (E) DLC1-3D binds RhoA-GTP in vitro less efficiently compared with 
DLC1-WT or DLC1-3A. DLC1 proteins were partially purified from transfected HEK 293T cells, and bound in vitro to RhoA-GTPγS, a nonhydrolyzable 
GTP analogue. GAP-dead DLC1-R677A, which has reduced binding in this assay (Jaiswal et al., 2014), was included as a control. Graph shows relative 
RhoA-GTPγS binding to each DLC1 mutant from three experiments. Parametric two-tailed t tests were performed for statistical analysis. (F) Expression of GFP 
and GFP-tagged DLC1 mutants for E. (G) In A549 cells, inactive DLC1 is mainly a monomer; AKT inhibition converts DLC1 to an active dimer. Dimerization 
between DLC1-WT and DLC1-WT, DLC1-3A, or DLC1-3D mutant in the absence (control) or presence of MK-2206. (H) Graph shows relative dimerization 
of each DLC1 mutant, relative to DLC1-WT, from two experiments. Error bars in all graphs indicate the SD.
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immunodeficiency (NOD-SCID) mice. In both bioassays, MK-
2206 potently reduced the growth of GFP-DLC1-WT cells 
(Fig. 9 C, for mouse tumors; and Fig. S6, C and D, for agar 
growth), whereas its effects were less pronounced in GFP con-
trol cells. These results were correlated with MK-2206 reducing 
RhoA-GTP and its RhoA-dependent signaling (pMRLC level) 
in the GFP-DLC1-WT cells but not in the GFP control cells, al-
though the AKT activity was similarly reduced in both isogenic 
lines (Fig. 9 D). A separate experiment, which included H358 
cells stably expressing DLC1-3A and DLC1-3D in addition 
to those expressing DLC1-WT, confirmed the specificity of 
the Fig. 9 C results. MK-2206 treatment for 5 d decreased the 
size of DLC1-WT tumors by 69%, compared with decreases of 
18–20% for tumors expressing DLC1-3A, DLC1-3D, or vector 
control (Fig. S6, E and F).
Discussion
This study identified increased RhoA-GTP by RTK ligands 
(EGF, IGF-1, and insulin) as a previously unrecognized, but 
common, physiological determinant of RhoA activation. We 
found the kinase activity of AKT, which is stimulated by the 
cognate RTKs these ligands activate, is required for the in-
creased RhoA-GTP. DLC1, a tumor-suppressor gene that en-
codes a RhoGAP, is the key downstream target for the AKT 
kinase in this phenomenon, which also occurs in tumor cell lines 
that express DLC1 but not in those with down-regulated DLC1.
In DLC1-positive cells, AKT phosphorylated three 
serines in DLC1 (S298, S329, and S567, the AKT serines), 
which greatly attenuated its RhoGAP and tumor-suppressor 
activities in several bioassays. Analysis of single, double, and 
triple serine-to-alanine (nonphosphorylatable) and serine-to- 
aspartate (phosphomimetic) mutants of the three AKT serines 
indicated that each phosphorylation contributed to the reduc-
tion in those activities, suggesting an electrostatic mechanism. 
In cells expressing WT DLC1, AKT inhibition by MK-2206 
greatly reduced serine phosphorylation of DLC1 and RhoA-
GTP, specific changes that were not seen in cells expressing 
either of the triple mutants of the AKT serines treated with 
MK-2206. In contrast to the RTK ligands, increased RhoA-
GTP induced by LPA, which is mediated by G protein– 
coupled receptors, occurs by a distinct mechanism that is not 
associated with AKT activation or DLC1.
A notable feature of the AKT serines in DLC1 is that 
they are located in the linker region of DLC1, rather than in 
the RhoGAP domain, which is necessary and sufficient for the 
RhoGAP activity of DLC1 (Healy et al., 2008). To explore 
the mechanism by which those phosphorylations outside the 
RhoGAP domain can reduce the RhoGAP activity, we studied 
complex formation between the RhoGAP domain and WT or 
serine mutants of the linker region after their cotransfection in 
cells and in vitro by immobilization-free MST to compare rel-
ative binding efficiencies of those polypeptides. The data led 
us to conclude the phosphorylations of the AKT serines induce 
strong binding between the linker region and the RhoGAP 
Figure 8. The closed conformation of the DLC1-3D mutant affects its subcellular localization. (A–D) Colocalization of GFP-tagged DLC1 constructs (green) 
with FA protein vinculin (red) in stable H1703 cells. Unlike the GFP control (A), DLC1-WT (B) and DLC1-3A (C) efficiently colocalize to FAs, whereas 
DLC1-3D (D) and GFP control (A) do not. (E–H) Experimental conditions were similar to A–D, but cells were treated with MK-2206. MK-2206 increases co-
localization of DLC1-WT to FAs, but does not influence GFP control, DLC1-3A, or DLC1-3D. Images are representative of most cells. Averaged overlapping 
colocalization coefficient means ± SD (below each panel) was calculated from ≥10 cells per condition randomly selected from several fields. Bar, 20 µm.
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domain, which places DLC1 in a closed, inactive conforma-
tion that is mainly monomeric (Fig. 9 E) and reduces RhoA-
GTP binding to DLC1, tensin and talin binding to DLC1, and 
DLC1 colocalization to FAs. That mechanism is essentially 
the opposite of what we found from phosphorylation of four 
serines in the DLC1 linker region by CDK5 (Tripathi et al., 
2014), which placed DLC1 in an open, active conformation by 
decreasing an autoinhibitory interaction between the linker re-
gion and the RhoGAP domain.
Our results differ from, and extend in important ways, pre-
vious studies that DLC1 is an AKT substrate. Hers et al. (2006) 
found that insulin induces phosphorylation in the rat version of 
DLC1 at S322 (which corresponds to S329 in human DLC1) 
and showed that phosphorylation was mediated by AKT, but 
they did not examine the possible downstream consequences. 
Ko et al. (2010) made the important observation that AKT re-
duces the tumor-suppressor activity of DLC1 and concluded 
that phosphorylation of S567 by AKT was responsible for 
that reduction because they did not detect phosphorylation of 
S298 or S329. Under our growth conditions, however, all three 
AKT serines are phosphorylated in cells, as documented with 
the DLC1 mutants and mass spectrometry results. Consistent 
with these findings, our analysis of phosphoproteomic data 
in the National Cancer Institute’s Clinical Proteomic Tumor 
Analysis Consortium (CPT AC) database indicates a signifi-
cant correlation in human breast cancer (Mertins et al., 2016) 
between AKT activity, as measured by phosphorylation of 
AKT T308 and S473, and phosphorylation of DLC1 S298 and 
S329 (P = 0.03; the CPT AC screen did not identify the peptide 
with the S567 residue).
Figure 9. MK-2206 can reactivate DLC1 and has greater antitumor activity in DLC1-positive tumors than it has in DLC1-negative tumors. (A) Tumors from 
MMTV-PyMT–positive mice have high AKT activity (lanes 4–6), high RhoA-GTP (lanes 4–6), and high RhoA/ROCK-dependent myosin phosphorylation 
(pMRLC pT18/pS19; lanes 4–6) compared with mammary epithelium from pregnant mice (lanes 1–3 in the same blot). MK-2206 treatment for 5 d re-
duced AKT activity, RhoA-GTP, and pMRLC pT18/pS19. Total AKT, Rho, and MRLC were similar in each condition. (B) MK-2206 reduces tumor weight. 
Graph shows tumor weight means ± SD (C and D) MK-2206 suppresses tumor growth more strongly in DLC1-positive tumors than it does in DLC1-negative 
tumors. Isogenic H358 stable clones expressing DLC1-WT or GFP control were injected subcutaneously into NOD-SCID mice. When tumors were ∼1.0 cm 
in diameter (4 wk for GFP- and 10 wk for DLC1-expressing cells), mice were treated with MK-2206 for 5 d. (C) MK-2206 reduced tumor weight by more 
than 70% in DLC1-positive tumors (left), but <20% in DLC1-negative tumors (right). Parametric two-tailed t tests were performed for statistical analysis. Error 
bars in the graph indicate the SD. (D) MK-2206 efficiently inhibited AKT activity in DLC1-positive and DLC1-negative tumors. MK-2206 reduced RhoA-GTP– 
and RhoA-ROCK–dependent myosin phosphorylation in DLC1-positive tumors (left) but not in the DLC1-negative tumors (right). (E) Model for regulation 
of DLC1 by AKT. Top part shows that, in the absence of serine phosphorylation (S298, S329, and S567) by AKT, DLC1 has an open conformation with 
high RhoGAP activity; forms dimers; strongly binds RhoA-GTP, tensin, and talin; and colocalizes to FAs. Bottom part shows that, in the presence of serine 
phosphorylation by AKT, DLC1 has a closed conformation with low RhoGAP activity; is mainly a monomer; weakly binds RhoA-GTP, tensin, and talin; and 
poorly colocalizes to FAs.
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Ko et al. (2010) concluded the reduced tumor-suppressor 
activity induced by AKT was not associated with a decrease 
in the RhoGAP activity of DLC1 because they did not de-
tect an increase in RhoA-GTP. However, we developed strong 
evidence that AKT-dependent phosphorylation of DLC1 is 
associated with an increase in RhoA-GTP in nontransformed 
lines, tumor-derived lines, and the MMTV-PyMT transgenic 
breast cancer model. One possible way to reconcile the 
RhoA-GTP conclusions of Ko et al. (2010) with ours is that 
they focused on the RhoA-GTP levels of the single DLC1-
S567D mutant; in agreement with their results, we found 
the RhoGAP activity in that mutant was close to that of WT 
DLC1. In our experiments, the serine-to-aspartate mutation of 
at least two of the three AKT serines was needed to detect a 
decrease in RhoGAP activity.
EGF treatment of some cell lines has been reported to 
have somewhat different effects on DLC1. Cao et al. (2012) 
reported that EGF can activate DLC1 in MCF10A breast ep-
ithelial cells via a mechanism that includes replacement of 
tensin-3 binding to DLC1 with CTEN (C-terminal tensin-like) 
binding, a process that takes much longer than the one de-
scribed here. MCF10A is the only nontransformed line we 
have examined in which endogenous DLC1 is inactive (Trip-
athi et al., 2014), so it may not be surprising that it behaves 
differently. Ravi et al. (2015) examined the effects of EGF 
on a DLC1-negative, HeLa-derived cancer line. In agreement 
with our data, EGF treatment of the parental line had no effect 
on RhoA-GTP. However, they found that, although transient 
transfection with WT DLC1 RhoGAP did not alter RhoA-
GTP, EGF treatment of those transfectants resulted in reduced 
RhoA-GTP, in contrast to the increased RhoA-GTP we ob-
served for endogenous DLC1 and the stable transfectants in 
several cell lines we tested. The two-step mechanism that they 
concluded was responsible for their observation is unrelated to 
the one described here.
Our observations may have therapeutic implications in 
cancer. The AKT-induced attenuation of the tumor-suppressor 
function of DLC1 is potentially reversible because AKT inhi-
bition can decrease phosphorylation of the three AKT serines 
and reactivate DLC1. In the transgenic MMTV-PyMT cancer 
model, which we determined has constitutive activation of AKT 
and high RhoA-GTP, pharmacologic AKT inhibition by MK-
2206 decreased phosphorylation of the AKT serines in DLC1, 
decreased RhoA-GTP, and reduced tumor size. We extended 
those results by testing an isogenic version of a tumor line with 
constitutively active AKT that either expressed DLC1 or did 
not express DLC1. Similar to the MMTV-PyMT, MK-2206 re-
duced RhoA-GTP and the size of xenograft tumors from the 
DLC1-positive subline. However, in the DLC1-negative subline, 
AKT inhibition by MK-2206 did not change RhoA-GTP and 
had only marginal antitumor activity. The results strongly imply 
the antitumor activity observed in the DLC1-positive line was at-
tributable, at least in part, to reactivation of DLC1 by MK-2206.
These findings highlight the potential utility of monitor-
ing the reactivation of tumor-suppressor genes when inhibiting 
an oncoprotein, such as AKT, which has a clinical potential that 
is still being explored (Nitulescu et al., 2016). Such reactiva-
tion may also be relevant for inhibition of other oncoproteins 
that inactivate tumor-suppressor genes indirectly or directly, as 
occurs with CDK4/6 and pRB via phosphorylation (Hamilton 
and Infante, 2016) or MDM2 and p53 via the ubiquitin system 
(Wasylishen and Lozano, 2016).
Materials and methods
Plasmid constructs
GFP-tagged DLC1 WT (GFP-DLC1-WT); DLC1 GAP-dead mutant 
(GFP-DLC1-R718A); GFP-tagged DLC1 fragments encoding DLC1 
residues 1–492, 500–1091, 1–110, 80–200, 80–300, 80–400, 400–500, 
609–850, 850–1091, and 609–878; and GFP-DLC3 were constructed 
by PCR and subcloned into a modified pEGFP-C1 vector (Takara Bio 
Inc.) through Kpn1-NotI sites, as described (Qian et al., 2007). GST-
tagged tensin and talin fragments were described previously (Qian 
et al., 2007; Li et al., 2011). GFP-DLC2 was a gift from M. Mowat 
(Manitoba Institute of Cell Biology, Winnipeg, Manitoba, Canada). 
A series of individual and combined serine-to-Alanine (S-to-A) and 
serine-to-aspartate (S-to-D) mutations were introduced into full-length 
DLC1-WT and into DLC1 fragments encoding residues 80–600, using 
a site-directed mutagenesis kit (Agilent Technologies). Table S1 lists 
the primers used. Full-length DLC1 and DLC1 (80–600) linker region 
fragments, with or without 3A or 3D mutations, were engineered into 
the PEBG vector with BamHI and NotI, resulting in GST-tagged DLC1 
constructs. All PCR regions were confirmed by sequencing.
Antibodies and fluorescent probes
The following antibodies were purchased from Cell Signaling Tech-
nology: AKT mouse (2920), AKT rabbit (4691), phospho-AKT-pS473 
rabbit (4060) and phospho-AKT-pT308 rabbit (13038), phospho-Akt 
substrate (RXXS*/T*) rabbit (9614), phosphorylated Thr18/Ser19 
pMRLC rabbit (3674), and GAP DH (2118) rabbit. Two DLC1 anti-
bodies, which gave similar results, were used: one, generated in our 
laboratory (DLC1 antibody; clone 428; 24), and the other, DLC1 
mouse mAb (612021), purchased from BD. pEGFR-Y845 rabbit 
(ab5636), MRLC mouse (ab11082), GFP mouse (ab1218), and GFP 
rabbit (ab290) antibodies were purchased from Abcam. RhoA mouse 
(ARH04) and pMRLC goat (sc-12896) antibodies were obtained from 
Cytoskeleton, Inc., and Santa Cruz Biotechnology, Inc., respectively. 
The phospho-serine mouse (612547) antibody was purchased from 
BD. Anti–rabbit and anti–mouse IgG HRP-linked secondary antibod-
ies were obtained from GE Healthcare. Alexa Fluor 568 anti–rabbit 
IgG, Alexa Fluor 488 anti–mouse IgG, Alexa Fluor 488 phalloidin, and 
DAPI were purchased from Thermo Fisher Scientific.
Cell lines, culture conditions, and DNA transfection
HEK 293T, human skin epithelial H2071, human lens epithe-
lial FHL124, and human fibroblastic H1634 cells were cultured in 
DMEM supplemented with 10% FBS. Human breast cancer lines 
(BT549, MCF10A1Ca1h, MDA-MB-468, and T47D) and NSC LC 
lines (H1703, H157, A549, and H358, provided by C.  Harris, Na-
tional Cancer Institute, Bethesda, MD) were cultured in RPMI-1640 
supplemented with 10% FBS. Transient transfections were performed 
with Lipofectamine 3000 (Thermo Fisher Scientific) and cultured for 
48 h. Stable clones expressing GFP or DLC1 mutants were made by 
transfecting H1703 or H358 cells with Lipofectamine 3000, followed 
by G418 selection (0.9 µg/ml).
siRNA transfection and treatment of cells with EGF, insulin, IGF-1, 
LPA, and AKT-inhibitor MK-2206
To suppress DLC1 expression, cells were transfected with 160 nM 
of DLC1 siRNAs or with scrambled control siRNAs, and harvested 
48  h later. Suppression of protein expression, with two different 
siRNAs, was confirmed by immunoblotting. Validated siRNAs for 
human DLC1 (Hs_DLC1 siRNA_5, SI03219909, and Hs_DLC1 
siRNA_11, SI04952213) were from QIA GEN, as were negative 
control siRNAs (control siRNA 1, 1027280; and control siRNA 2, 
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1027310). The sequence for each DLC1 siRNA was as follows: 
Hs_DLC1 siRNA _5 sense sequence: 5′-CGA UGU CGU AAU UCC 
UAU ATT-3′; Hs_DLC1_5 antisense sequence: 3′-CGG CUA CAG 
CAU UAA GGA UAU-5′; Hs_DLC1_11 sense sequence: 5′-GGA 
GUG UAG GAA UUG ACU ATT-3′; Hs_DLC1_11 antisense sequence: 
3′-gaCCU CAC AUC CUU AAC UGAU-5′.
The final concentration of ligands was as follow: EGF (100 ng/
ml), insulin (100 nM), IGF-1 (100 ng/ml), and LPA (1.0 µM). All four 
ligands were procured from Sigma-Aldrich. AKT inhibitor MK-2206 
(used at 10  µM) was from Selleck Chemicals. After overnight incu-
bation in serum-free medium, cells were treated with the indicated li-
gands or inhibitors for 15–120 min.
In vitro AKT kinase assay
Lysates from transfected cells were IP with GFP antibody, and immu-
nopellets were sequentially washed once with high-salt HNTG buffer 
(20 mM Hepes, 500 mM NaCl, 0.1% Triton X-100, and 10% glycerol), 
twice with low-salt HNTG buffer (20 mM Hepes, 150 mM NaCl, 0.1% 
Triton X-100, and 10% glycerol), and once with kinase reaction buf-
fer (35 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EGTA, 1% Tween 
20, 0.1 mM sodium vanadate, and 1 mM DTT). The kinase reaction 
was performed in 30 µl of reaction buffer containing 15 µM cold ATP, 
2.5 µCi γ-[32P]ATP, and 100 ng of recombinant active AKT (EMD 
Millipore) at 30°C for 45 min. The reaction was stopped by adding 
10  µl of 4× Laemmli sample buffer and heating at 95°C for 5 min. 
Proteins were separated by gel electrophoresis and autoradiographed to 
detect 32P incorporation.
RhoA-GTP (Rhotekin-Rho binding domain pull-down) assay
A Rho activation assay kit (EMD Millipore) was used to measure GTP-
bound RhoA, as described previously (Tripathi et al., 2014). In brief, 
equal amounts (1,000 µg) of each cell lysate were incubated with 30 
µg GST-Rhotekin Rho-binding domain coupled to glutathione-agarose 
beads for 45 min. Beads were washed three times with washing buffer, 
samples were subjected to 4–12% SDS-PAGE, transferred onto nitro-
cellulose membranes (Thermo Fisher Scientific), and detected by IB, 
using RhoA antibody (ARH04 from Cytoskeleton, Inc., and 05–778 
from EMD Millipore; clone 55).
ROCK (Rho kinase) assay
Cells were fixed and harvested in 10% TCA containing 10 mM DDT. 
Pellets were dissolved in 10 µl of 1 M Tris base and mixed with 100 µl of 
extraction buffer (8 M urea, 2% SDS, 5% sucrose, and 5% 2-mercaptoeth-
anol). Equal amounts of protein from each cell extract were subjected 
to 10% SDS-PAGE, transferred onto nitrocellulose membranes, and in-
cubated with an antibody specific for phospho-myosin binding subunit 
(phospho-Thr853-MYPT1) or myosin binding subunit (MYPT1), and 
bands were visualized by enhanced chemiluminescence. ROCK activity 
was expressed as the ratio of phospho-MYPT1 to total MYPT1.
RhoGAP activity assay
GFP-tagged DLC1 constructs were purified by IP using GFP rabbit 
polyclonal (ab290) antibody from transfected cells using a high-strin-
gency buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM MgCl2, 
NP-40 [0.5%], 1 mM DTT, and protease and phosphatase inhibitor). 
Highly purified Rho was bound to γ-labeled [P32]GTP. The GTPase-ac-
celerating activity (RhoGAP activity) of various DLC1 mutants at each 
time point was determined by incubating with GTP-bound RhoA at 
18°C with shaking and removing samples at the indicated time points. 
The guanidine nucleotides were separated by chromatography on cel-
lulose filter paper dissolved in buffer. The γ-P32 signal was then deter-
mined, and the net GTP hydrolysis was calculated.
In vivo pull-down assay, coIP, and immunoblotting
Cells were transiently cotransfected with plasmids expressing GST or 
the indicated GST fusion constructs together with GFP or the indicated 
GFP-DLC1 constructs. 48 h after transfection, cells were lysed with 
golden lysis buffer. The cleared supernatants were collected, and a small 
portion of supernatants was taken to determine the protein concentration 
using the DC protein assay (Bio-Rad Laboratories). For the pull-down 
assay, 1.0 mg of total protein from each cell extract was used, to which 
30 µl of glutathione sepharose-4B slurry (GE Healthcare) was added, 
with continuous rotation for 3 h at 4°C. The pellets were sequentially 
washed once with golden lysis buffer, once with high-salt HNTG buffer, 
and twice with low-salt HNTG buffer. The beads were incubated with 
30 µl Laemmli sample buffer, subjected to 10% SDS-PAGE, transferred 
onto nitrocellulose membranes (Thermo Fisher Scientific), and detected 
by IB using specific antibodies. A portion of the cell extracts was used 
as a loading control to verify expression of the GFP fusion proteins and 
the GPF control. For coIP experiments, equal amounts of protein from 
each cell lysate were precleared with protein G slurry (Thermo Fisher 
Scientific) and incubated with the indicated antibodies or control IgG 
for 1 h at RT. After incubation, 30 µl of protein G slurry was added to 
each immune reaction and rotated at 4°C overnight. The immunopellets 
were washed three times with IP buffer. Coimmunoprecipitated proteins 
were eluted by boiling for 5 min in 30 µl Laemmli sample buffer con-
taining 5% (vol/vol) 2-mercaptoethanol. Eluted proteins were resolved 
on a NuPage 4–12% BisTris gel and detected by immunoblotting using 
specific antibodies. Immunoreactive bands were detected by enhanced 
chemiluminescence (ECL-Plus; GE Healthcare) using HRP-linked anti–
rabbit or anti–mouse secondary antibodies (1:5,000 dilutions).
MST
Binding efficiency of DLC1 N terminus to its RhoGAP domain was 
studied by MST (Khavrutskii et al., 2013; Seidel et al., 2013) using a 
Monolith NT.115 instrument (NanoTemper). Serial 1:1 dilutions of the 
DLC1 N-terminal fragment (80–600) WT or its combined 3A or 3D 
mutant versions were mixed with each aliquot and a fixed volume of 
fluorescent GFP-tagged RhoGAP domain [GFP-DLC1 (609–878)], the 
resulting probes were placed in glass capillaries (NanoTemper), and 
assayed with “blue” light-emitting diode excitation (excitation, 460–
480 nm, and emission, 515–530 nm), observing the fluorescence signal 
upon start of illumination with a pin-point infrared laser (1,480 nm). 
The MST plots for each capillary set were analyzed by NT.Analysis 
1.5.41 software (NanoTemper), providing fluorescence intensity versus 
protein concentration plots for each binding pair. The inflection point of 
those plots corresponds to the dissociation constant of each interaction.
Immunofluorescent staining
Transiently or stably transfected cells were seeded onto glass chambers, 
incubated for 24 h, and fixed with 4% PFA for 20 min. Fixed cells were 
permeabilized with 0.25% Triton X-100 in PBS and then blocked with 
3% BSA in PBS for 2 h. The cells were incubated with a 1:200 dilution 
of the indicated primary antibodies at 4°C overnight. After being thor-
oughly washed in PBS, the cells were incubated with the appropriate 
1:250 Alexa Fluor–conjugated secondary antibodies for 1 h. To visual-
ize actin or nuclei, cells were incubated with phalloidin (1:50) or DAPI 
(1:2,500) for 1 h. After staining, the cells were thoroughly washed with 
PBS and mounted with gel-mounting solution (BIO MEDA).
Fluorescent confocal microscopy
Confocal microscopy of fluorescent-labeled cells was performed with 
a microscope (LSM 780; ZEI SS) with an excitation wavelength of 488 
nm to detect transfected GFP fusion proteins. Alexa Fluor probes were 
viewed with excitation wavelengths of 488 (Alexa Fluor 488) and 568 
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(Alexa Fluor 568) nm. Images were made at RT using photomultiplier 
tubes with a Plan-Apochromat 63×/1.4 NA oil-differential, interfer-
ence-contrast, objective lens with a 2× magnifier to produce a 125× 
magnification. The colocalization of two proteins was analyzed by 
confocal software (ZEN 2012; ZEI SS). For quantification of represen-
tative morphology in each group, ∼15 cells per condition, randomly 
selected from several fields, were analyzed. The Mander’s overlapping 
colocalization coefficient means ± SD were calculated and are shown 
below each figure panel. The overlapping colocalization coefficients 
can range from 0 to 1, where 0 means no colocalization and 1 means 
full colocalization of the two proteins. The images were minimally pro-
cessed for levels/contrast adjustment in DAPI panels, and the adjust-
ment was performed on entire images using Photoshop CC software 
(Adobe). The adjustments do not enhance, erase, or misrepresent any 
information present in the original images.
PLA
PLA was used to visualize proximity colocalization (<40 nm) of DLC1 
and AKT in NSC LC lines using the Duolink Detection kit (Olink Pro-
teomics). The cells were fixed with 4% PFA for 20 min at RT and then 
incubated with 0.25% Triton-X-100 for 5 min. After blocking with 3% 
BSA, cells were incubated overnight at 4°C with rabbit anti–DLC1 
(1:100) plus mouse anti–AKT (1:500) antibodies. After washing, cells 
were incubated with secondary antibodies with PLA probes (MIN US 
probe–conjugated anti–rabbit IgGplus PLUS probe–conjugated anti–
mouse IgG (Olink Proteomics). Circularization and ligation of the oli-
gonucleotides in the probes were followed by an amplification step. 
A complementary fluorescent-labeled probe was used to detect the 
product of the rolling-circle amplification. Slides were mounted with 
Duolink II mounting medium containing DAPI. Images were obtained 
with an LSM 780 (ZEI SS) using ZEN software (ZEI SS). The colocal-
ization PLA dots in cells were counted using ImageJ software (Na-
tional Institutes of Health). Quantifications are given as means ± SD.
Mass spectrometry analysis
Lysates from HEK 293T cells expressing GFP-tagged DLC1 con-
structs, either untreated or treated with the MK-2206 AKT inhibitor, 
were IP with GFP antibody. The immunopellets were resolved on a 
NuPage 4–12% BisTris gel. The Coomassie-stained DLC1 gel band 
was destained, and proteins were reduced, alkylated, and digested with 
trypsin or LysC as described (Shevchenko et al., 2006). Digested pep-
tides were further desalted using StageTip C18 columns (Rappsilber 
et al., 2007) and were analyzed on a Q-Exactive instrument (Thermo 
Fisher Scientific) equipped with a Proxeon EASY-nLC 1,000 UHP LC 
System. Liquid chromatography–tandem mass spectrometry data were 
searched against a human Refseq database using MaxQuant v1.3.0.5 
(Cox and Mann, 2008; Cox et al., 2011) with carbamidomethylation 
as a fixed modification and the following variable modifications: ox-
idation of methionine, acetylation of protein N termini, deamidation 
of asparagine, and phosphorylation of serine, threonine, and tyrosine 
residues. For peptide identification, we applied a 1% false-discovery 
rate using a target–decoy search strategy (Elias and Gygi, 2010).
Cell migration assay
Cell migration was measured by 6.5-mm-diam Falcon cell culture in-
serts (8 µm pore size; BD). Transiently transfected cells or stable clones 
were trypsinized, resuspended in serum-free RPMI-1640 medium, and 
transferred to the upper chamber (7.5 × 104 cells in 300  µl). 600  µl 
of 10% FBS in RPMI-1640 was placed in the lower chamber. After 
18 h incubation, the cells remaining on the upper surface of the insert 
were removed five times with a cotton swab moistened in PBS. Mi-
grated cells on the lower surface were fixed in methanol for 20 min 
at RT, followed by staining with 2% crystal violet (Sigma-Aldrich) in 
methanol for 30 min, destained, examined, and photographed by mi-
croscopy. For quantification, migrated cells were solubilized with 1% 
Triton X-100 and counted in a spectrophotometer at an OD of 590 nm.
Soft agar and anchorage-independent growth assay
For soft agar assays, a 0.6% agar (BD) base in RPMI-1640 medium was 
placed in 60-mm dishes for 1 h at RT. 1.0 × 105 cells were mixed with 
complete medium containing 0.4% agar and placed over 0.6% basal 
agar in 60-mm dishes. Cells were grown for 3 wk, and colonies were 
photographed microscopically and quantified with a colony counter. 
For clonogenic assays, 0.6 × 105 cells were seeded in six-well plates 
and cultured in 0.9 µg/ml G418 RPMI-1640 medium with 10% FBS for 
3 wk. Colonies were fixed, stained with 4% crystal violet, and counted.
In vivo tumorigenesis and treatment of mice with AKT inhibitor MK-2206
The mouse studies were approved by the National Cancer Institute An-
imal Care and Use Committee and were conducted in compliance with 
the approved protocols. For the tumor xenograft, H358 stable clones 
expressing GFP, GFP-DLC1-WT, GFP-DLC1-3A, GFP-DLC1-3D, 
and GFP-DLC1-R718A were trypsinized, washed with cold PBS, 
diluted to 108 cells/ml with serum-free medium/Matrigel basement 
membrane matrix (BD) at a ratio of 3:1, and injected subcutaneously 
into NOD-SCID mice (1.0 × 107 cells/injection). The animals were 
monitored for tumor growth, and tumor masses were weighed (in 
grams) 6 wk after injection.
For mice with xenograft tumors, H358 stable clones expressing 
various GFP-tagged DLC1 constructs were trypsinized, washed with 
cold PBS, diluted to 108/ml with serum-free medium/Matrigel base-
ment membrane matrix (BD) at a ratio of 3:1, and injected subcutane-
ously into NOD-SCID mice (1.0 × 107 cells/injection). When tumors 
were 0.5–1.0 cm, mice were treated with MK-2206 or vehicle control 
for 5 d, and the remaining tumor tissues were then excised, weighed, 
and processed for biochemical assays. For MMTV-PyMT mice, tumors 
were randomly divided into two groups. Mice were treated orally with 
50 mg/kg MK-2206 AKT inhibitor for five consecutive days or the ve-
hicle control. The remaining tumor tissues were then excised, weighed, 
and processed for biochemical assays.
Data analysis
At least two independent experiments were performed for all in vitro 
analysis. Immunoblots were quantified by densitometric scanning 
using ImageQuant software. Results are expressed as density means ± 
SD from two or three experiments. All experiments were designed with 
matched control conditions within each experiment. Data distribution 
was assumed normal, but that was not tested formally. For statistical 
analysis, parametric two-tailed t tests were performed using PRI SM 
software (version 7.0a; GraphPad Software), and P < 0.05 was consid-
ered statistically significant.
Online supplemental material
Fig. S1 shows that EGF-induced AKT activity, which increases RhoA-
GTP through DLC1 and AKT, regulates all three DLC family members. 
Fig. S2 shows that insulin and ILGF-1 also induce AKT activity and in-
crease RhoA-GTP through DLC1. However, LPA induces RhoA-GTP 
in a DLC1-independent manner and does not activate AKT. Fig. S3 
shows DLC1 and AKT form a protein complex in human cell lines, and 
the complex formation does not require enzymatic activity of AKT. Fig. 
S4 shows all three members of the DLC gene family, DLC1, DLC2, 
and DLC3, are AKT substrates. The phosphorylation of the three AKT 
serines in DLC1 (S298, S329, and S567) was confirmed by mass spec-
trometry. Fig. S5 shows that the AKT phenotype was dominant over the 
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CDK5 phenotype. PyMT-positive tumors have high AKT activity, high 
RhoA-GTP, and high MRLC phosphorylation. Fig. S6 shows that the 
MMTV-PyMT–positive tumors have high AKT activity, high RhoA-
GTP, and high DLC1 phosphorylation. Treatment with MK-2206 in-
hibits colony formation, growth in soft agar, and tumor formation in 
mice of DLC1-WT transfected cells only, but does not alter anchor-
age-independent growth or tumor formation by cells transfected with 
the GFP control, DLC1-3A, DLC1-3D, or DLC1-R718A.
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Figure S1. EGF-induced AKT activity increases RhoA-GTP through DLC1; AKT regulates all three DLC genes. (A) EGF increased RhoA-GTP, but not total Rho, 
in the MCF10Ca1h breast cancer cell line and H157 in the NSC LC line; both of which express DLC1. The graph shows the relative RhoA-GTP means ± 
SD from three experiments. Parametric two-tailed t tests were performed for statistical analysis. (B) Experimental conditions were similar for MDA-MB-468 
breast cancer cell line and A549 NSC LC cell line, which were DLC1 negative. EGF did not alter RhoA-GTP in the DLC1-negative lines. Error bars in the 
graph indicate the SD. (C and D) siRNA knockdown of DLC1 in H1634 and BT549 cells resulted in RhoA-GTP being unresponsive to EGF. Knockdown of 
DLC1 expression by siRNAs (top) in H1634 (C) and BT549 (D) cells. EGF-stimulated EGFR phosphorylation and AKT activity in both DLC1-expressed and 
DLC1-knocked-down cells. However, EGF did not alter the total AKT or GAP DH, whether DLC1 was expressed or knocked down. Knockdown of DLC1 
abrogated the ability of EGF to increase RhoA-GTP. EGF stimulates RhoA-GTP only in DLC1-positive cells (compare lanes 1 and 2 in the RhoA-GTP blot), but 
not in DLC1-knocked down cells (compare lanes 3 and 4 in the RhoA-GTP blot) for H1634 (C) and BT549 (D). EGF did not alter total Rho whether DLC1 
was expressed or knocked down (bottom). (E) Relative expression of DLC1 protein (top) in the indicated cell lines. GAP DH was used as a loading control. 
(F) EGF increased the phosphorylation of AKT serines in DLC1 (pSer) without changing total DLC1. Lysates from H1703 cells treated with or without EGF 
were IP with DLC1 antibody, followed by IB with phospho-AKT substrate-specific (top) or DLC1 (bottom) antibodies. (G) EGF substantially increased AKT 
activity, as measured by pAKT-S473 (top), without changing the AKT level (bottom). GAP DH was used as a loading control. (H) Time course of EGF-induced 
responses to EGFR activity, AKT activity, and RhoA-GTP. There is good correlation between increased EGFR activity (top; measured by EGFR phosphory-
lation at tyrosine 845), increased AKT activity (as measured by phosphorylation of AKT-serine 473 [pAKT-S473]), and increased RhoA-GTP activity in all 
DLC1-positive lines by EGF treatment. EGF did not alter the total AKT (middle) and the total Rho (bottom). GAP DH was used as a loading control. (I) A549 
cells, transfected with GFP, DLC1, DLC2, or DLC3 constructs, were treated without or with AKT inhibitor MK-2206. Compared with GFP vector, transfection 
of DLC1, DLC2, or DLC3 decreased RhoA-GTP (control), but not total Rho (control). MK-2206 reduced AKT activity (pAKT-S473) but not total AKT or total 
Rho. The effect of MK-2206 on RhoA-GTP in DLC2- and DLC3-transfected cells was less than its effect on DLC1-transfected cells (MK-2206; GFP-DLCs). 
Expression of GFP, DLC1, DLC2, and DLC3 in the presence or absence of MK-2206 (middle).
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Figure S2. Insulin and IGF-1 induce AKT activity and increase RhoA-GTP through DLC1; LPA induces RhoA-GTP in a DLC1-independent manner and does 
not activate AKT. (A) Insulin increased RhoA-GTP (lower middle) in DLC1-positive BT549, H1703, and 2071 cell lines but not in DLC1-negative T47D or 
H358 lines, although insulin treatment increased AKT activity in all lines (top). Insulin did not alter the total AKT (upper middle) and the total Rho (bottom). 
GAP DH was used as a loading control. (B) Experimental conditions and data display are as in A, except cells were treated with IGF-1. IGF-1 increased 
RhoA-GTP in DLC1-positive BT549, H1703, and 2071 lines but did not alter RhoA-GTP in DLC1-negative T47D or H358 lines (lower middle), although 
IGF-1 treatment increased AKT activity in all lines (top). (C) LPA increased RhoA-GTP in both DLC1-positive and DLC1-negtive lines (bottom middle). How-
ever, LPA treatment did not alter AKT activity (top), total AKT (top middle), or total Rho level (bottom). (D) LPA treatment did not stimulate AKT activity (top), 
unlike EGF treatment, in H1703 and H157 lines. However, LPA increased RhoA-GTP comparable to EGF treatment (lower middle) in both lines. (E) LPA 
increased RhoA-GTP (bottom middle) in H1703 cells in which DLC1 expression has been knocked down by siRNAs (top). However, LPA did not alter AKT 
activity (top middle) and total Rho level (bottom). GAP DH was used as loading control.
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Figure S3. DLC1 and AKT forms a protein complex in human cell lines, and complex formation does not require enzymatic activity of AKT. (A) Endogenous 
protein complex between DLC1 and AKT. Lysates from H157 cells were IP with DLC1 or mock IgG antibodies followed by IB with AKT (top) or DLC1 (bottom) 
antibodies. WCE, whole cell extract. (B) The endogenous protein complex between DLC1 and AKT was confirmed by reciprocal coIP. (C and D) Experimen-
tal conditions and data display were similar to A, but for nontransformed lines H2017 (C) and H1634 (D). (E) Some AKTs that are associated with DLC1 
are enzymatically active. Endogenous protein complex between DLC1 and kinase-active AKT (pAKT-S473) in H157 cells. Lysates were IP with pAKT-S473 
antibody followed by IB with DLC1 (top) or pAKT-S473 (bottom) antibodies. (F) Complex formation between DLC1 and AKT did not require AKT enzymatic 
activity. The experimental conditions were similar to B, except that the protein complex between DLC1 and AKT was analyzed in the absence or presence 
of MK-2206 in H1703 cells. (G) MK-2206 treatment inhibited AKT activity (measured by pAKT-S473) in H1703 cells. (H) The experimental conditions 
and data display were similar to F, but for H157 cells. (I) MK-2206 treatment inhibited AKT activity in H157 cells. (J) MK-2206 is a specific AKT inhibitor 
because AKT activity (measured by pAKT-S473) was inhibited by MK-2206 in both H1703 and H358 lines but not by inhibitors of ERK (SCH772984) or 
MEK (U0126). (K–N) Stimulation of AKT by EGF treatment did not increase the AKT/DLC1 protein complex in H1703 (K) and H2071 (M) cell lines. EGF 
stimulated AKT activity, but not total AKT, in H1703 (L) and H2071 (N) lines. GAP DH was used as a loading control.
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Figure S4. DLC1, DLC2, and DLC3 are AKT substrates. (A) In vitro AKT kinase assay. (A, top) IP DLC1-WT was strongly phosphorylated by recombinant 
AKT kinase (lane 2), as detected with 32P autoradiography. GFP control gave no phosphorylation signal (lane 1). DLC2 (lane 3) and DLC3 (lane 4) were 
also phosphorylated, but weakly compared with DLC1. (A, bottom) Expression of GFP vector and GFP-tagged DLC constructs. (B) DLC1 phosphopeptides 
identified by mass spectrometry. Annotated tandem mass spectrometry spectra are shown for the three phosphopeptides containing phosphorylated S298, 
S329, and S567. b-Type fragments are shown in blue and y-type fragments in red. Water- and ammonia-loss peaks are shown in yellow, and neutral 
phosphate losses are indicated with asterisks. The fragment ions observed allow full localization of the phosphorylation sites on the serine residues noted 
in each peptide. Spectra were annotated using the Viewer software of the MaxQuant 1.3.0.5 software package.
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Figure S5. AKT phosphorylation of DLC1 is phenotypically dominant over CDK5 phosphorylation of DLC1; MMTV-PyMT–positive tumors have high AKT 
activity, high RhoA-GTP, and high phosphorylation of DLC1 serines. (A) Effect of CDK5 inhibitor roscovitine on RhoGAP activity of DLC1 mutants for AKT 
sites. RhoA-GTP (top) and total Rho (middle) in A549 cells expressing the indicated DLC1 mutants (bottom). RhoA-GTP was reduced by DLC1-WT or 
DLC1-3A mutant compared with GFP control and DLC1-3D mutant (control). Roscovitine induced an increase in RhoA-GTP in DLC1-WT (compare lanes 
2 and 6) but did not influence RhoA-GTP in GFP, DLC1-3A, or DLC1-3D mutant for AKT sites (roscovitine), although roscovitine efficiently suppressed the 
CDK5 kinase activity, as measured by CDK5-pY15, in each transfectant (middle). Roscovitine did not affect the CDK5 level. (A, bottom) Expression of each 
transfectant. (B) Effect of MK-2206 on RhoGAP activity of DLC1 mutant for CDK5 sites. RhoA-GTP (top) and total Rho (middle) in A549 cells expressing the 
indicated DLC1 mutants (bottom). RhoA-GTP was reduced by DLC1-WT and DLC1-4D mutant (for CDK5 sites) compared with GFP control and DLC1-4A 
mutant (control). MK-2206 reduced RhoA-GTP in DLC1-WT, as well as in 4A and 4D mutants of the CDK5 sites, but not in GFP control (MK-2206). MK-
2206 efficiently suppressed the AKT activity, as measured by pAKT-S473, in each transfectants (middle), but not total AKT. (B, bottom) Expression of each 
transfectant. (C and D) The decreased binding of tensin and talin protein to DLC1-3D was not an intrinsic property of the transfected linker region by itself. 
Immunoblots from HEK 293T cells cotransfected with HA-tagged full-length talin (C) or GFP-tagged full-length tensin (D) and GST, GST-DLC1 (80–600)-WT, 
GST-DLC1 (80–600)-3A, or GST-DLC1 (80–600)-3D fragment was pulled down with GST antibody and IB with HA antibody (C) or GFP antibody (D; top). 
IB with HA or GFP (bottom) antibodies to show expression of HA or GFP-tagged construct. IB with GST antibodies (C and D, right) to show the expression 
of GST-tagged DLC1 constructs. The GST-DLC1 (80–600)-3D bound talin and tensin as efficiently as GST-DLC1 (80–600)-WT. Each immunoblot is repre-
sentative of at least two independent experiments. (E) Tumors from MMTV-PyMT-positive mice have high AKT activity (measured by pAKT-S473; top, lanes 
5–8), high RhoA-GTP (middle, lanes 5–8), and high RhoA-ROCK-dependent pMRLC (lanes 5–8) compared with mammary epithelium from pregnant mice 
(compare with lanes 1–4 in the respective blot). However, total AKT, total Rho, and total MRLC levels from each tissue were similar. GAP DH was used 
as a loading control. (F) Lysates from mammary epithelium of pregnant mice or MMTV PyMT-positive tumors were IP with DLC1 antibody followed by IB 
with phospho-AKT substrate-specific (pSer) antibody. WCE, whole cell extract. IP DLC1 from MMTV PyMT-positive tumors was strongly phosphorylated 
compared with IP DLC1 from mammary epithelium of pregnant mice.
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Figure S6. AKT inhibition has greater antitumor activity in DLC1-positive tumors. (A and B) Lysates from MMTV PyMT–positive tumors treated with or with-
out MK-2206 were IP with DLC1 antibody followed by IB with (pSer) phospho-AKT substrate-specific (A) or DLC1 (B) antibodies. WCE, whole cell extract. 
MK-2206 treatment reduced serine phosphorylation (pSer) of DLC1 (A; compare lanes 1 and 2) without changing the DLC1 expression (B; compare lanes 
1 and 2). (C) Anchorage-independent growth of H358 cells stably transfected with DLC1 mutant in the absence or in the presence of MK-2206. MK-2206 
treatment inhibited growth and colony formation in soft agar of DLC1-WT transfected cells. However, MK-2206 treatment did not influence the anchor-
age-independent growth or the number of soft agar colonies of GFP control, DLC1-3A, DLC1-3D, or GAP-dead DLC1-R718A transfected cells. Bar, 2 mm. 
(D) Quantification of agar colonies (>0.4 mm) in the indicated groups from three independent experiments. Parametric two-tailed t tests were performed for 
statistical analysis. MK-2206 treatment induced a significant decrease (P < 0.01) in soft agar colonies in DLC1-WT. However, MK-2206 treatment did not 
influence the soft agar growth of GFP, DLC1-3A, DLC1-3D, or DLC1-R718A transfected cells. Error bars in the graph indicate the SD. (E) Mice with tumors 
were treated with MK-2206 (50 mg/kg for 5 d) 8 wk after injecting the stable transfectants. Photographs of xenograft tumors from mice after treatment for 
5 d with MK-2206. (F) Graph shows tumor weight (in grams) means ± SD for each group in the presence or absence of MK-2206 treatment. The numbers 
below the graph represent the percent reduction in tumor weight by MK-2206 treatment compared with respective untreated group.
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Table S1. Primers used for engineering DLC1 plasmids
Primer name Sequence (5′–3′)
DLC1-S298A-Forward GAG GAG CGT TGC CAA CTC CAC GCA GACC
DLC1-S298A-Reverse GGT CTG CGT GGA GTT GGC AAC GCT CCTC
DLC1-S298D-Forward GAG GAG CGT TGA TAA CTC CAC GCA GACC
DLC1-S298D-Reverse GGT CTG CGT GGA GTT ATC AAC GCT CCTC
DLC1-S329A-Forward CCC GGA GCC TCG CTG CGT GCA ACA AGC
DLC1-S329A-Reverse GCT TGT TGC ACG CAG CGA GGC TCC GGG
DLC1-S329D-Forward CCC GGA GCC TCG ATG CGT GCA ACA AGC
DLC1-S329D-Reverse GCT TGT TGC ACG CAT CGA GGC TCC GGG
DLC1S567A-Forward CTG AGA TGG CAC GCT TTC CAG AGC TCA
DLC1S567A-Reverse TGA GCT CTG GAA AGC GTG CCA TCT CAG
DLC1S567D-Forward CTG AGA TGG CAC GAT TTC CAG AGC TCA
DLC1S567D-Reverse TGA GCT CTG GAA ATC GTG CCA TCT CAG
